Trials / Completed
CompletedNCT06386211
Bioavailability Study of Magne-B6 New Formulation
Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Relative Bioavailability Study of Magne-B6 New Formulation Versus Magne-B6 Solution in Healthy Male and Female Subjects in Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Opella Healthcare Group SAS, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the relative bioavailability of two Magne-B6 preparations, in fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAGNE-B6 Oral Solution | Oral solution. |
| DRUG | MAGNE-B6 New Formulation Tablet | New formulation tablet. |
Timeline
- Start date
- 2024-07-03
- Primary completion
- 2024-08-24
- Completion
- 2024-08-24
- First posted
- 2024-04-26
- Last updated
- 2025-09-12
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06386211. Inclusion in this directory is not an endorsement.